期刊文献+

DF/DCF方案治疗晚期胃癌的临床观察

暂未订购
导出
摘要 目的:观察多西他赛联合5-氟尿嘧啶持续静脉滴注(DF)方案和多西他赛联合顺铂、5-氟尿嘧啶持续静脉滴注(DCF)方案治疗晚期胃癌的临床效果和毒副反应。方法:经病理组织学证实的晚期胃癌56例随机分为两组,DF组29例,采用多西他赛60mg/m^2,D1;5-氟尿嘧啶425mg/m^2.d,静脉输液泵连续滴注,D1-5,21天为一个周期。DCF组27例,在DF方案基础上,加用顺铂60mg/m^2,D1,21天为一个周期。所有患者至少接受2个周期的化疗。结果:DF组总有效率48.3%,其中CR1例,PR13例;DCF组总有效率51.9%,其中CR1例,PR 13例。两组有效率比较差异无统计学意义(P〉0.05)。两组主要毒副反应为骨髓抑制、脱发、消化道反应和关节肌肉酸痛等,DCF组消化道反应显著大于DF组(P〈0.01)。结论:DF/DCF方案治疗进展期胃癌的疗效相近,但DF方案毒副反应更易被患者接受,是治疗进展期胃癌的较好方案之一。
出处 《交通医学》 2010年第6期656-657,共2页 Medical Journal of Communications
  • 相关文献

参考文献8

  • 1罗兰T.斯基尔.癌症化疗手册[M].6版.北京:人民卫生出版社,2005:721-722.
  • 2孙燕.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2008:597.
  • 3王峰,李梅,钱俐,沈浮,茅国新.伊立替康在晚期胃癌二线化疗中的应用[J].南通大学学报(医学版),2009,29(2):120-121. 被引量:1
  • 4吴芳,张弘纲.多西紫杉醇在晚期胃癌的临床应用[J].癌症进展,2007,5(3):276-281. 被引量:42
  • 5Roth AD,Maibach R,Martinelli G,et al.Docetaxel(Taxotere)-cisplatin (TC):an effective drug combination in gastric carcinoma.Swiss Group for Clinical Cancer Research(SAKK),and the Euronpean Institute of Oncology(E10)[J].Ann Oncol,2000,11(3):301-306.
  • 6刘凡,茅国新,钱俐,李梅,沈浮.多西他赛联合FOLFOX4方案治疗进展期胃癌的临床观察[J].交通医学,2010,24(2):174-174. 被引量:6
  • 7Tetzlaff ED,Cheng JD,Ajani JA.Review of docetataxel in the treatment of gastric cancer[J].Ther Clin Risk Manag,2008A(5):999-1007.
  • 8Ajani JA.Docetaxel for gastric and esophageal carcinomas[J].Oncology(Williston Park),2002,16(2):89-96.

二级参考文献37

  • 1夏盛成,王爱坤,王学兵,孙永芳,严仁俊.全胃切除术62例临床分析[J].南通大学学报(医学版),2005,25(5):357-358. 被引量:2
  • 2[1]Sulkes A,Smyth J,Sessa C,et al.Docetaxel(Taxotere) in advanced gastric cancer:Results of a phase Ⅱ clinical trial.EORTC Early Clinical Trials Group.Br J Cancer,1994,70:380
  • 3[2]Einzig AI,Neuberg D,Remick SC,et al.Phase Ⅱ trial of docetaxel (Taxotere) in patients with adenoearcinoma of the upper gastrointestinal tract previously tmtreated with cytotoxic chemotherapy:The Eastern Cooperative Oncology Group(ECOG)resuits of protocol E1293.Med Oncol,1996,13:87
  • 4[3]Mavroudis D,Kourousis C,Androuiakis N,et al.Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor(G-CSF):A phase Ⅱ trial.Am J Clin Oncol,2000,23:341
  • 5[4]Bang YJ,Kang WK,Kang YK,et al.Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:A phase Ⅱ trial.Jpn J Clin Oncol,2002,32:248
  • 6[5]Taguchi T,Sakata Y,Kanamaru R,et al.Late phase Ⅱ clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer:A Japanese Cooperative Study Group Trial(group A).Gan To Kagaku Ryoho,1998,25:1915
  • 7[6]Vanhoefer U,Wilke H,Harstrick A,et al.Phase Ⅱ study of docetaxel as second-line chemotherapy in metastatic gastric cancer.Proc Am Soc Clin Oncol,1999,35th annual meeting:Abstract 1163
  • 8[7]Giuliani F,Gebbia V,De Vita F,et al.Docetaxel as salvage therapy in advanced gastric cancer:A phase Ⅱ study of the Gruppo Oncologico Italia Meridionale(G.O.I.M.).Anticancer Res,2003,23:4219
  • 9[8]Graziano F,Catalano V,Baldelli AM,et al.A phase Ⅱ study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer.Ann Oncol,2000,11:1263
  • 10[9]Burris HA.3rd.Docetaxel in combination with fluorouracil for advanced solid tumors.Oncology(Williston Park),1997.11:50

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部